WuXi STA Shanghai site passes GMP inspection by Europe's MPA

摘要

WuXi STA,the Chinese API and finished dosage form CDMO,said its new drug product manufacturing facility in the Waigaoqiao Free Trade Zone of Shanghai,opened in 2018,passed its first GMP inspection by the European Medical Products Agency(MPA).The WuXi AppTec subsidiary said the success demonstrates the quality of its drug product services.As a global CDMO,WuXi STA has previously passed inspections in the US,Canada,Switzerland,China,Australia and New Zealand to supply APIs and advanced GMP intermediates for partners.Of these,its API and advanced intermediate manufacturing facility in Shanghai and API R&D and manufacturing facility in Changzhou have been inspected by the FDA.